The New Jersey products liability attorneys at Breslin and Breslin are reporting that Stryker Corp. on Monday said that it has resolved multiple product-liability lawsuits related to its Rejuvenate and ABGII hip implants, which the company had recalled in 2012 because of the potential for the devices to corrode and cause inflammation in tissue in and around the implant.
Bergen County residents who have suffered injuries from faulty DePuy hip replacements or other defective Johnson & Johnson products will likely be interested to learn that J&J recently set aside $600 million in preparation for a potential settlement over kickbacks allegations. This is in addition to the $5.3 billion that has reportedly already been reserved for potential products liability and kickback claims in relation to other J&J medications and medical devices.
According to a 2011 report from the U.S. Food and Drug Administration (FDA), the number of "adverse event" reports for medical devices has increased by about 15 percent every year for the last 10 years. If you are a regular reader of our New Jersey personal injury blog, you are likely not surprised by this increase.
Slow and steady seems to be the name of the game in the main personal injury lawsuit against DePuy Orthopaedics, a division of New Jersey company Johnson & Johnson, over its faulty artificial hip replacement products.
According to a recently released document, New Jersey company Johnson & Johnson began taking action to phase out the use of its metal-on-metal artificial hips just weeks after the receiving a letter from U.S. Food and Drug Administration. In that letter, the agency reportedly turned down Johnson's application to sell the medical product in the United States, and told the company to submit additional safety data if it wanted to pursue the application.
In recent weeks, we have written extensively on the issues surrounding the DePuy Orthopaedics articular surface replacement (ASR) metal-on-metal hip replacement joints. Essentially, these faulty medical products have caused thousands of people in New Jersey and throughout the country to suffer debilitating pain and lasting injury as a result of friction in the joint's metal components.
Earlier this week, we began an in-depth look into the convoluted process by which Johnson & Johnson and its unit DePuy Orthopaedics sought FDA approval for its articular surface replacement devices, or ASRs. Initially, the FDA rejected the medical product, stating that additional clinical study was necessary to determine whether the product was safe.
New documents have revealed that DePuy Orthopaedics, a unit of New Jersey-based Johnson & Johnson, continued to sell faulty hip replacement joints internationally after they were rejected for sale by the U.S. Food and Drug Administration. At the same time, DePuy sold a similar defective product in the U.S. after was approved through the FDA's 501(k) loophole, which we detailed extensively in a previous product liability blog post.
Recently, the faulty metal-on-metal hip replacement joints manufactured by DePuy Orthopaedics, a unit of New Jersey-based Johnson & Johnson, have become the subject of scrutiny and debate after causing pain and injury to thousands of patients. According to a few new studies, those defective products may continue to cause harm long after they are removed from the body.